about us

Endevica Bio is a highly-curated team of experts and thought-leaders in peptide therapeutics, designing drugs that are potent, selective, and bioavailable.

Our small, focused team of chemists, biologists and computational chemists responds quickly to new data, adapts to the evolving landscape of modern drug discovery, and follows the science to groundbreaking therapies.

Endevica Bio currently has two assets: a clinical-stage drug for cancer cachexia that is entering P2 trials in 2025, and an advanced preclinical therapeutic for obesity that shows efficacy in non-human primates.

OUR TEAM

Leadership

Russell potterfield

CHIEF EXECUTIVE OFFICER

daniel
marks